Table: 1

|  |  |
| --- | --- |
| Demographics of SLE Patients treated with Cyclophosphamide | |
| ***Variables*** | **N (%)** |
|
| Age (Years) |  |
| n | 31 |
| Mean | 37.9 |
| STD | 8.6 |
| Ethnicity |  |
| African American | 8 (25.8%) |
| Asian | 2 (6.4%) |
| Caucasian | 6 (19.4%) |
| Hispanic | 15 (48.4%) |
| Sex |  |
| Female | 27 (87.1%) |
| Male | 4 (12.9%) |

\*\*Total 42 courses of cyclophosphamide in 31 patients; denominator used is 42.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Table 2 Incidence rate using Poisson-regression model patients treated with Cyclophosphamide. | | | |  |
| ***Type of infection*** | ***Number of Infection onsets*** | ***Incidence rate (per100) person-Year*** | ***(95% CL) Per100 person-year*** |  |
| Over all Infection | 42 | 67.42 | (44.34 - 102.48) |  |
| UTI | 8 | 24.31 | (11.56 - 51.14) |  |
| Pos. Blood Cx | 2 | 0.78 | (0.01 - 74.95) |  |
| Bacterial PNA | 2 | 1.32 | (0.04 - 39.89) |  |
| Pneumocystis carinii PNA | 1 | 1.29 | (0.02 - 44.28) |  |
| Mucocutaneous Fungal Infection | 3 | 5.62 | (1.07 - 29.44) |  |
| URI | 14 | 44.65 | (24.82 - 80.35) |  |
| Mucocutaneous Bacterial Infection | 1 | 2.41 | (0.21 - 27.55) |  |
| Mucocutaneous Viral Infection | 8 | 20.8 | (8.54 - 50.65) |  |
| Viral Gastroenteritis | 3 | 9.13 | (2.67 - 31.21) |  |
| \*Incidence rates are the number of events per 100 person-years. | | |  |  |
| The age and ANC adjusted Poisson-regression model were used to analyze the incidence rate and | | | | |
| their 95% confidence intervals (95*%* Cls). | | | | |

\*\*Total 42 courses of cyclophosphamide in 31 patients; denominator used is 42.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Table-3 Comparing steroids on incidence of infection using time dependent multivariate analysis patients treated with Cyclophosphamide | | | | |
| **Type of Infection** | **Number of Events** | **Cumulative Steroid (prednisone mg equivalent) Mean ± STD** | ***P* value** |  |
| UTI |  |  | 0.0240\*\* |  |
| Infection | *n=7* | 13773.6 ± 7076.4 |  |  |
| No Infection | *n=35* | 11432.1 ± 5433.6 | ` |  |
| Pos. Blood Cx |  |  | 0.0394\*\* |  |
| Infection | *n=2* | 9010.8 ± 4967.4 |  |  |
| No Infection | *n=40* | 12021.9 ± 5795.6 |  |  |
| Bacterial PNA |  |  | 0.0247\*\* |  |
| Infection | *n=2* | 17566.7 ± 11030.9 |  |  |
| No Infection | *n=40* | 11546.7 ± 5417.2 |  |  |
| Pneumocystis carinii PNA |  |  | 0.0150\*\* |  |
| Infection | *n=1* | 23305.0 ± 0.0 |  |  |
| No Infection | *n=41* | 11554.2 ± 5484.9 |  |  |
| Mucocutaneous Fungal Infection |  |  | 0.0544 |  |
| Infection | *n=3* | 8418.3 ± 2392.4 |  |  |
| No Infection | *n=39* | 12054.8 ± 5822.8 |  |  |
| URI |  |  | 0.0168\*\* |  |
| Infection | *n=13* | 13649.2 ± 7371.2 |  |  |
| No Infection | *n=29* | 11039.2 ± 4749.2 |  |  |
| Mucocutaneous Bacterial Infection |  |  | 0.0216\*\* |  |
| Infection | *n=1* | 18360.0 ± 0.0 |  |  |
| No Infection | *n=41* | 11678.9 ± 5710.9 |  |  |
| Mucocutaneous Viral Infection |  |  | 0.0113\*\* |  |
| Infection | *n=8* | 15292.3 ± 5935.1 |  |  |
| No Infection | *n=34* | 10949.1 ± 5419.5 |  |  |
| Viral Gastroenteritis |  |  | 0.0132\*\* |  |
| Infection | *n=3* | 17584.4 ± 7008.6 |  |  |
| No Infection | *n=35* | 11373.1 ± 5457.4 |  |  |
| ***P Value (\*) was obtained using Cox hazard proportional time to event model*** | | | | |

\*\*Total 42 courses of cyclophosphamide in 31 patients; denominator used is 42.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Table 4 Infection rates for opportunistic and serious infection patients treated with Cyclophosphamide | | | | | | | |
| ***Type of infection*** | | ***Number of Infection*** | ***Incidence rate (per100) person-Year*** | | ***(95% CL) Per100 person-year*** | | |
|  | |  |  | |  | | |
| **Opportunistic Infections** | | **12** | **39.648** | | **(22.03 - 71.39)** | | |
|  | |  |  | |  | | |
| PJP | | 1 | 1.290 | | (0.037 - 44.280) | | |
| Mucosal candidiasis | | 2 | 4.624 | | (0.875 - 24.420) | | |
| Fungal skin infection | | 1 | 0.000 | | (0.000 - 0.000) | | |
| Shingles | | 5 | 9.107 | | (2.292 - 36.192) | | |
| Mucocutaneous HSV-1 infection | | 3 | 7.477 | | (1.945 - 28.752) | | |
|  | |  |  | |  | | |
| **Serious Infections** | | **5** | **12.948** | | **( 4.42 - 39.94)** | | |
|  | |  |  | |  | | |
| Line sepsis | | 2 | 0.797 | | (0.009 - 73.224) | | |
| UTI | | 2 | 4.279 | | (0.694 - 28.388) | | |
| Serious PJP Infection | | 1 | 1.290 | | (0.037 - 44.280) | | |
| Incidence rates are the number of events per 100 person-years.  The age and ANC adjusted Poisson-regression model were used to analyze the incidence rate and their 95% confidence intervals (95*%* Cls).  \*\*Total 42 courses of cyclophosphamide in 31 patients; denominator used is 42.  Table-5 Multivariate Analysis comparing Age, WBC and ANC associated with and without infections with Cyclophosphamide therapy | | | | | | | | |
| **Factor** | **Infection** | | | **No Infection** | | ***P* value** | **Hazard Ratio** | |
| **(*n=24*)** | | | **(*n=18*)** | |  | |
| Age (years) | 34.5 ± 8.6 | | | 39.9 ±9.2 | | 0.1158 | 1.050 | |
| WBC | 7.7 ± 4.2 | | | 8.1 ± 3.2 | | 0.5536 | 1.225 | |
| ANC | 6.0 ± 4.0 | | | 6.3 ± 3.0 | | 0.7035 | 0.874 | |